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SUMMARY
Background
Morphological, haemodynamic and clinical stages of cirrhosis have been proposed,
although no deﬁnite staging system is yet accepted for clinical practice.
Aim
To investigate whether clinical complications of cirrhosis may deﬁne different
prognostic disease stages.
Methods
Analysis of the database from a prospective inception cohort of 494 patients.
Decompensation was deﬁned by ascites, bleeding, jaundice or encephalopathy.
Explored potential prognostic stages: 1, compensated cirrhosis without oeso-
phago-gastric varices; 2, compensated cirrhosis with varices; 3, bleeding without
other complications; 4, ﬁrst nonbleeding decompensation; 5, any second decom-
pensating event. Patient ﬂow across stages was assessed by a competing risks
analysis.
Results
Major patient characteristics were: 199 females, 295 males, 404 HCV+, 377 com-
pensated, 117 decompensated cirrhosis. The mean follow-up was
145  109 months without dropouts. Major events: 380 deaths, 326 oesophago-
gastric varices, 283 ascites, 158 bleeding, 146 encephalopathy, 113 jaundice, 126
hepatocellular carcinoma and 19 liver transplantation. Patients entering each prog-
nostic stage along the disease course were: 202, stage 1; 216, stage 2; 75 stage 3; 206
stage 4; 213 stage 5. Five-year transition rate towards a different stage, for stages 1–
4 was 34.5%, 42%, 65% and 78%, respectively (P < 0.0001); 5-year mortality for
stages 1–5 was 1.5%, 10%, 20%, 30% and 88% respectively (P < 0.0001). An explor-
atory analysis showed that this patient stratiﬁcation may conﬁgure a prognostic sys-
tem independent of the Child–Pugh score, Model for End Stage Liver Disease and
comorbidity.
Conclusion
The development of oesophago-gastric varices and decompensating events in cir-
rhosis identify ﬁve prognostic stages with signiﬁcantly increasing mortality risks.
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INTRODUCTION
The natural history of cirrhosis is characterised by a
silent course until decompensation, when the progressive
deterioration of liver function causes a rapid decline of
life expectancy. The early stage of the disease is usually
referred to as ‘compensated cirrhosis’, while the late one,
deﬁned by the appearance of ascites, bleeding, encepha-
lopathy or jaundice, is termed ‘decompensated cirrhosis’.
Due to the strikingly different survival,1, 2 compensated
and decompensated cirrhosis are considered two distinct
clinical entities.3
In recent years, a prognostic staging system of cir-
rhosis has been proposed, based on the observation that
the patient outcome may be different according to the
major clinical manifestations of the disease. Four stages
have been proposed at the Baveno IV consensus
conference:4 stage 1, compensated cirrhosis without
oesophageal varices; stage 2, compensated cirrhosis with
varices; stage 3, ascites with or without varices; stage 4,
bleeding with or without ascites. The four stages are
characterised by a signiﬁcant increase in the risk of
death.5 However, it has been shown that decompensated
patients with ascites do have a signiﬁcantly poorer
outcome than those without ascites6 and it has been
therefore suggested that ascites should be a stratifying
variable for decompensated patients. In agreement with
this observation, a cohort study showed that 1-year
death risk was signiﬁcantly lower in patients with bleed-
ing alone than in patients with ascites and that patients
with ascites plus bleeding had the highest risk,7 thus
suggesting three stages for decompensated cirrhosis. A
position paper of the American Association for the
Study of Liver Disease has then reformulated the con-
cept of cirrhosis from a static to a dynamic one with
progression through biological, morphological and clini-
cal stages and has encouraged clinical research in this
sense.3 Other studies have conﬁrmed the concept of
clinical8, 9 and morphological10 stages along with a cor-
relation between morphological and clinical stages.11, 12
However, a deﬁnite staging system for cirrhosis,
widely applicable in clinical practice is not yet available.
We used the database from an inception cohort
study13, 14 to investigate whether a ﬁve-stage prognostic
system based on development of oesophageal varices,
bleeding, ascites and jaundice, allows classifying all the
observed patients according to different survival proba-
bilities within each stage. Competing risks of further
clinical events and transitioning rates across stages were
also investigated.
METHODS
To the aim of this study, we used a database drawn from
a prospective inception cohort study, whose protocol was
approved by the local ethics committee and based on the
experience of a previous study of the natural history of
cirrhosis performed at our Unit.15 The major characteris-
tics of the patient cohort are brieﬂy summarised below.
From June 1981 to June 1984, all the consecutive in- or
out-patients with newly diagnosed cirrhosis observed at
our Unit were included in the study and those still alive
are currently in follow-up. Patients were mostly referred
directly from the family physicians to ascertain a sus-
pected liver disease. The diagnosis of cirrhosis was biopsy
proven in 342 patients without ascites or coagulopathy. In
the remaining 152, diagnosis was based on typical ultraso-
nographic and laboratory ﬁndings with ascites (n = 78) or
oesophageal varices (n = 56) or a ﬁrm liver and spleno-
megaly on physical examination (n = 18). Patients with
Wilson disease (n = 4), haemocromatosis (N = 3), pri-
mary or secondary biliary cirrhosis (N = 5), or primary
sclerosing cholangitis (N = 3) or autoimmune hepatitis
(N = 6) were excluded. Six more patients were excluded
because of incomplete cirrhosis on histology. Therefore, a
total of 494 out of 521 patients were included.
HBsAg was determined by radioimmunoassay and a
serum sample from all the included patients was stored
at 80°C. Alcohol abuse was considered as a potential
cause of cirrhosis when a habitual intake of >80 g/day
for >5 years was admitted from the patient or his rela-
tives. When commercial kits for serum anti-hepatitis C
virus (HCV) were made available, all the stored sera
were assessed with enzyme linked immunosorbent assay.
Results are reported according to third generation assays.
After diagnosis of cirrhosis and informed consent to
participate in the study, all the patients completed the
initial study work-up including upper digestive endos-
copy, liver ultrasonography and laboratory tests if not
already performed in the diagnostic assessment. Fol-
low-up started immediately after the informed consent
and the initial study work-up was completed within
1 month. Endoscopy was then repeated every 2–3 years
in patients without oesophageal varices, ultrasonography
every 6–12 months, laboratory assessment every
6 months. Follow-up visits were repeated every 3–
6 months or earlier according to the clinical condition.
Loss to follow-up was prevented by recalling patients
who did not present at each planned follow-up visit. The
following clinical events were recorded: oesophageal vari-
ces, ascites, bleeding, encephalopathy, jaundice, hepato-
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cellular carcinoma, comorbidity and death. The diagnosis
of hepatocellular carcinoma was based on liver biopsy or
on two imaging tests or one imaging test plus alpha-foe-
toprotein >400 UI/mL.16
No speciﬁc treatment was given to compensated
patients free of varices. No patient received anti-viral
treatment for HCV (not deﬁnitely recommended for
cirrhotic patients along almost the entire study period),17
while lamivudine was given according to evolving recom-
mendations18 in 10 HBsAg-positive patients. Treatments
for variceal bleeding or its prophylaxis, ascites, spontane-
ous bacterial peritonitis, hepatorenal syndrome, portal
systemic encephalopathy, were given according to guide-
lines or recommendations from consensus conferences
available along the whole study period.19–21 Only 19
patients were transplanted because no transplantation
centre was available in Palermo before 1998, and only 12
were treated by trans-jugular intra-hepatic porto-sys-
temic shunt (TIPS).
Compensated cirrhosis was deﬁned by the absence of
bleeding (any episode of haematemesis or melena), asci-
tes on physical examination (conﬁrmed by a tap), jaun-
dice (serum bilirubin ≥3 mg/dL) or symptomatic
encephalopathy22 and decompensated cirrhosis by any of
these complications.1–3
Prognostic stages were deﬁned, according to major
manifestations of decompensation of the disease,
modifying The Baveno IV proposal4 as follows: stage 1,
compensated cirrhosis without varices; stage 2,
compensated cirrhosis with varices; stage 3, bleeding with-
out other disease complications; stage 4, ﬁrst nonbleeding
decompensating event; stage 5, any second decompensat-
ing event. Patients were considered within each stage until
the occurrence of a new event, marking the transition
towards a different stage. Hepatocellular carcinoma
(HCC) was not considered as a separate stage as it may
occur along the whole course of the disease and may be
associated with compensated as well as decompensated
cirrhosis.
Survival was assessed by the Kaplan–Meyer method23
and differences between patient subgroups were assessed
by the log-rank test. The cumulative incidence of major
clinical events was assessed by a competing risks
model,24 where death was the competing event. Time
zero for the analysis of outcome of each prognostic stage
was the time a patient entered that stage. Therefore,
patients leaving a stage, contributed to the assessment of
the outcome of the next stage they entered, so that each
patient may have contributed to the assessment of more
than one stage.
An exploratory analysis by the proportional hazards
Cox model25 was performed to investigate whether the
proposed stages may have an independent prognostic role
for death, when adjusting for the most important death
risk predictors already known.5 Proportional-hazards
assumption was tested by log-log plots inspection. A
full model approach was used to select variables in multi-
ple regression analyses to minimise the risk of overﬁt-
ting.26 Candidate predictors were set a priori among
important and widely accepted prognostic indicators in
cirrhosis:5 age, gender, aetiology of cirrhosis, albumin, bili-
rubin, International Normalised Ratio of prothrombin
activity, creatinine, platelet count, oesophago-gastric vari-
ces, ascites, porto-systemic encephalopathy, upper diges-
tive bleeding, hepatocellular carcinoma, Child–Pugh
score,27 Model for End Stage Liver Disease (MELD)28 and
comorbidity.29 Natural logarithm transformation was
needed for INR to achieve normal distribution. Three
models were performed to avoid the inclusion of poten-
tially redundant variables in the same model: model 1
excluding Child–Pugh score and MELD; model 2 includ-
ing Child–Pugh score and model 3 including MELD.
The aim of this prognostic analysis was purely explor-
atory. Therefore validation, or assessment of discrimina-
tion, calibration or comparison with previously known
prognostic scores was not planned.
Statistical analyses were performed by STATA 11.0
(©Stata Corporation, College Station, TX, USA) and R
2.11.1 (© 2010 R free software foundation: http://www.
r-project.org).
RESULTS
Overview of the cohort outcome
Patients’ characteristics at inclusion and clinical events
observed during the follow-up are reported in Tables 1–
5: overall, 377 had compensated and 117 decompensated
cirrhosis and aetiology was mostly from HCV. The mean
follow-up was 145  109 months without dropouts.
Survival was signiﬁcantly better in patients with com-
pensated than decompensated cirrhosis at diagnosis (Fig-
ure 1a). The competing risks analysis showed that
decompensation occurred before death in 58% of
patients with compensated cirrhosis, while only 10% died
before decompensation and 4% died at the ﬁrst decom-
pensating event (Figure 1b). Patients dying at their ﬁrst
decompensating event likely presented acute on chronic
liver failure (AoCLF), although available data in our
database did not allow to classify these patients accord-
ing to the recently proposed criteria for AoCLF.30 The
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cumulative incidence of the major ﬁrst clinical event
occurring in the 377 patients with compensated cirrhosis
is shown in Figure 1c: ascites (33%), bleeding (10%) and
HCC (9%) were the most frequent, while encephalopathy
and jaundice occurred as the ﬁrst clinical event in a
minority of patients. Mortality before decompensation
was mostly due to nonliver related causes, while after
decompensation it was mostly due to liver-related causes
(Table 5). Among the 109 patients who admitted alcohol
abuse, 77 stopped it promptly after inclusion in the
study, while 32 continued on intermittent moderate alco-
hol abuse before giving up. However, only ﬁve of 32 had
purely alcoholic cirrhosis while the remaining had alco-
holic plus viral aetiology, thus hampering a separate
analysis of the effect of alcohol withdrawal on outcome
in solely alcoholic cirrhosis.
Table 1 | Patient
characteristics at inclusion:
demographics, aetiology and
biochemistry
Characteristics
Compensated
(N = 377)
Decompensated
(N = 117)
Total
(N = 494)
Age 48.7  12.9 58.2  13.9 50.9  13.7
Male/female 221/156 74/43 295/199
Aetiology
Anti-HCV+ 251 47 298
HBsAg+ 18 4 22
Anti-HCV and HBsAg+ 20 8 28
Alcohol 6 9 15
Alcohol and anti-HCV+ 53 25 78
Alcohol and HBsAg+ 10 6 16
Cryptogenic 19 18 37
Biochemistry
Albumin, g/L* 37.8  5.9 30.4  5.7 36.02  6.6
Bilirubin, mg/dL*,† 1.2  0.5 2.9  3.7 1.6  2.0
Prothrombin%* 77  15 57  14 72  17
INR* 1.36  0.32 1.87  0.48 1.47  0.42
AST 9UNL, IU* 3.4  2.4 3.1  3.1 3.4  2.6
ALT 9UNL, IU* 4.7  3.8 2.4  3.3 4.2  3.8
Creatinine, mg/dL
0–1 372 99 471
1.1–2 5 18 23
Haemoglobin, g/dL* 14.2  2.3 11.9  5 13.6  3.3
Platelet count 9109/L* 150  66 130  69 145  67
* Mean  standard deviation.
† Ordinal scale of values with steps of 1 mg/dL.
Table 2 | Patient
characteristics at inclusion:
clinical parameters
Characteristics
Compensated
(N = 377)
Decompensated
(N = 117)
Total
(N = 494)
Child–Pugh class, A/B/C 290/84/3 8/60/49 298/144/52
Child–Pugh score* 5.9  1.1 9.1  1.8 6.6  1.8
MELD* 10.1  2.9 16.6  5.1 11.7  4.5
Oesophageal Varices 131 56 187
Small 98 19 117
Medium 21 17 38
Large 12 20 32
Gastric varices 5 3 8
Ascites – 94 94
Bleeding – 18 18
Encephalopathy – 22 22
Jaundice – 27 27
HCC 9 18 27
* Mean  standard deviation.
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Overall, 187 patients had oesophageal varices, eight
gastric varices; 243 were free of varices at diagnosis while
56 did not undergo endoscopy (30 refused and 26 were
not submitted to endoscopy because of advanced disease).
New varices developed in 131 of 243 patients free of vari-
ces at diagnosis with a cumulative 10- and 20-year inci-
dence of 44% and 53% respectively (Figure 1d). When
varices were ﬁrst detected either at diagnosis or during
follow-up, (N = 326) their size31 was small in 221, med-
ium in 42 and large in 34. Progression of variceal size was
observed in 96 of 292 patients with previously smaller var-
ices. Cumulative 10- and 20-year survival after develop-
ment of varices were 42% and 21% respectively
(Figure 1e). By contrast, 10- and 20-year mortality before
development of varices was 16% and 26% (Figure 1d).
Ten- and 20-year cumulative incidence of
decompensation in the 377 patients with compensated
cirrhosis at diagnosis were 42% and 62% respectively
(including 4% who died at decompensation, Figure 1b),
and were signiﬁcantly higher in patients with than in
those without varices (33% and 49% vs. 50% and 69%,
respectively, P < 0.0001; Figure 1f). A total of 341
decompensated patients (117 at inclusion) were observed
throughout the study: the ﬁrst decompensating event
was ascites in 202, bleeding in 75, ascites plus bleeding
in 27, encephalopathy in 20 and jaundice in 19.
Overall, bleeding occurred in 158 patients and
rebleeding in 57; the most frequent source was oesoph-
ageal varices either at ﬁrst or recurrent bleeding
(Table 4). The cumulative 20-year incidence of bleeding
was 29% while 45% died before bleeding; 5- and
10-year mortality after bleeding was 70% and 82%
(Figure 2a).
Ascites was present at diagnosis in 94 patients and
occurred in further 189 during the follow-up with a 10-
and 20-year cumulative incidence of 31% and 45%
respectively (Figure 2b). Therefore, a total of 283
patients with ascites were observed during the study
Table 3 | Comorbidity at
inclusionCharacteristics
Compensated
(N = 377)
Decompensated
(N = 117)
Total
(N = 494)
Comorbidity* 216 69 285
Coronary heart disease 10 7 17
Other heart disease 4 0 4
Arterial hypertension 20 1 21
Chronic renal failure 3 1 4
Urolithiasis 11 0 11
Obstructive pulmonary
disease
13 9 22
Diabetes 34 25 59
Other Endocrinological
or Metabolic†
10 2 12
Cholelithiasis 32 11 43
Peptic ulcer 2 3 5
Other digestive‡ 9 3 12
Haematological§ 16 1 17
Immunological¶ 10 3 13
Chronic infections** 10 0 10
Nonhepatic tumours 3 1 4
Neuro-psychiatric†† 16 2 18
Other 13 0 13
None 161 48 209
* For patients with >1 comorbid conditions, the one considered most severe was
recorded.
† Includes thyroid diseases, overweight, hyperlipidemia, osteoporosis, diabetes insipidus.
‡ Includes achalasia, oesophagitis, irritable bowel, colonic diverticular disease, pancrea-
titis, oesophageal stricture, early gastric cancer, previous intestinal surgery.
§ Includes thalassaemic diseases, spherocytosis, porﬁrias, polyglobulia, idiopatic throm-
bocytopoenia.
¶ Includes allergic disorders, psoriasis, sjogren, lupus erythematosus.
** Includes AIDS, tuberculosis, urinary or prostate infection, echinococcus.
†† Includes migraine, depression, psychosis, epilepsy.
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(Table 4). Two- and 5-year cumulative mortality rates
after occurrence of ascites, were 38% and 78% respec-
tively (Figure 2b).
HCC developed overall in 126 patients (26%). The
20-year cumulative incidence was 18% (Figure 2c). Over-
all HCC developed before decompensation in 51 patients
and after decompensation in 75. Two- and 5-year mor-
tality after occurrence of HCC was respectively 74% and
91% (Figure 2c); corresponding ﬁgures when HCC
developed in a compensated stage were 52% and 85%
Table 4 | Major outcome
events during the whole follow-
up (including clinical
presentation), according to
compensated or
decompensated stage at
diagnosis*
Clinical event
Compensated
(N = 377)
Decompensated
(N = 117)
Total
(N = 494)
N (%) N (%) N (%)
Oesophageal varices 224 (59) 76 (65) 300 (61)
Gastric varices 20 (5) 6 (5) 26 (5)
Ascites 174 (46) 109 (93) 283 (57)
Upper digestive bleeding 107 (28) 51 (43) 158 (32)
Source of bleeding†
Oesophageal varices† 77 (72) 39 (76) 116 (73)
Gastric varices† 6 (6) 4 (8) 10 (6)
Portal hypertensive gastropathy† 7 (7) 3 (6) 10 (6)
Other† 10 (9) 2 (4) 12 (8)
Undeﬁned† 7 (7) 3 (6) 10 (6)
Rebleeding 41 (11) 16 (14) 57 (12)
Source of rebleeding‡
Oesophageal varices‡ 21 (51) 9 (56) 30 (52)
Gastric varices‡ 2 (5) 2 (13) 4 (7)
Portal hypertensive gastropathy‡ 5 (12) 1 (6) 6 (10)
Other‡ 7 (17) 1 (6) 8 (14)
Undeﬁned‡ 6 (15) 3 (19) 9 (16)
Encephalopathy 86 (23) 60 (51) 146 (30)
Jaundice 56 (15) 57 (49) 113 (2)
Hepatocellular carcinoma 94 (25) 32 (27) 126 (26)
Liver transplantation 17 (5) 2 (2) 19 (4)
* Numbers are the total of events observed across the whole study, including the
events which deﬁned patients as compensated or decompensated at inclusion.
† Percentage refers to the total of patients who bled.
‡ Percentage refers to the total of patients who rebled.
Table 5 | Causes of death according to compensated or decompensated stage at diagnosis
Clinical event
Compensated (N = 377)
N (% of deaths) Decompensated (N = 117) Total (N = 494)
Death*
While
compensated*
After
decompensation* N (% of deaths) N (% of deaths)
Total deaths 64 202 114 380
Liver failure 4 (6) 67 (33) 38 (33) 109 (27)
Variceal bleeding 7 (11) 33 (16) 25 (21) 65 (17)
Sepsis 4 (6) 7 (3) 7 (6) 18 (5)
Hepatocellular carcinoma 4 (6) 63 (31) 30 (26) 97 (26)
Neoplasia 10 (16) 7 (3) 2 (2) 15 (4)
Stroke 12 (19) 5 (2) 1 (1) 18 (5)
Myocardial infarction 5 (8) 2 (1) 0 (0) 7 (2)
Other nonliver related 13 (20) 10 (5) 7 (6) 29 (8)
Unknown 5 (8) 8 (4) 7 (6) 22 (6)
* For patients with compensated disease at inclusion in the study (N = 377), the number who died after decompensation (i.e. in
the decompensated phase of the disease) or at a decompensating event, is reported in the separate sub-column.
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and in a decompensated stage 90 and 97% (P < 0.00001)
(Figure 2d).
The cumulative incidence of encephalopathy and of
jaundice are shown in Figure 2e–f, together with mortal-
ity after the development of each.
Prognostic stages of cirrhosis
The number of patients entering each of the ﬁve prog-
nostic stages (at diagnosis or during the follow-up) is
reported in Figure 3 together with 20-year incidence of
competing events per each stage. Five-year transitioning
intensity and mortality per each prognostic stage is
reported in Table 6.
There were 202 patients with compensated cirrhosis
without oesophageal varices (stage1). After 20 years, 163
had disease progression, while 39 were still in this stage.
Fourteen patients bled in this stage: 10 bled from varices
which were not present at previous endoscopy (1 to
3 years before); no varices were found in the remaining
four patients in whom portal hypertensive gastropathy
was the most likely source of bleeding, although
there was no active bleeding at the time of endoscopy.
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Cumulative Incidence
of decompensation %
Varices N = 136
P < 0.0001
No varices 211
(f)
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of event %
Figure 1 | Twenty-year survival and cumulative incidence of clinical events. Cumulative incidence is computed by
competing risks analysis and each curve represents the probability of each speciﬁc outcome summed to the outcome
probability represented in the next curve below. Survival curves are computed by the Kaplan–Meier method. The x-
axis represents time in months and the numbers below the x-axis are patients at risk. (a) Survival of the whole series
and, respectively, of compensated and decompensated patients at diagnosis. (b) Cumulative incidence of
decompensation. Death and death at the time of ﬁrst decompensation are shown as competing events. (c)
Cumulative incidence of events presenting as a ﬁrst event in 377 patients with compensated cirrhosis at the
diagnosis. Twenty-year proportions of patients presenting each ﬁrst event are reported in the box. (d) Cumulative
incidence of oesophageal varices. Death is shown as a competing event. Arrows indicate the 20-year incidence of the
two competing events. (e) Survival of patients after development of varices. (f) Cumulative incidence of
decompensation in patients with and without varices at diagnosis.
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Development of varices and ascites were the most fre-
quent events occurring in this stage. After 20 years, mor-
tality in the stage was 10%, while 20% of patients were
still alive in the stage (Figure 3a).
Compensated cirrhosis with oesophageal varices (stage
2), was diagnosed in 137 patients at diagnosis and 79
(seven undetermined at diagnosis) developed varices
before decompensation, during the follow-up. Therefore,
overall 216 patients entered this stage. Major events in
this stage were bleeding and ascites. After 20 years, mor-
tality in the stage was 18%, while 19% of patients were
still in the stage (Figure 3b).
Overall, 158 patients bled during the follow-up (18 at
diagnosis of cirrhosis). Of them, 75 bled before the occur-
rence of any other decompensating event, thus entering in
stage 3. The 20-year cumulative incidence of rebleeding
was 19% (mean rebleeding time 28  46 months). Five
patients (6.5%) were still in this stage and did not rebleed
at 20 years. Ascites was the most frequent event and
20-year mortality in the stage was 23% (Figure 3c).
There were 63 patients with one nonbleeding decom-
pensating event at diagnosis and 143 developed one
such event during follow-up. Therefore, 206 patients
entered stage 4, 163 with ascites, 23 with jaundice and
21 with encephalopathy. Further events occurred overall
in 196 patients, bleeding and encephalopathy being the
most frequent; 20-year mortality in the stage was 39%
(Figure 3d).
Overall, 213 patients developed a second decompen-
sating event thus entering stage 5, mostly from stages 4
and 3, although 17 and 13 patients respectively, came
from stage 2 and 1, presenting with two events at the
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25%
% surviving with HCC
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Compensated
       N = 51
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N = 467
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(c)
(d) (e) (f)
Figure 2 | Twenty-year cumulative incidence (competing risks plots) of events along the course of cirrhosis and
survival (Kaplan–Meier plots) after each relevant event. Per each cumulative incidence curve death is the competing
event. Arrows indicate the 20-year incidence of the competing events. In the panels, the x-axis represents the
observation time in months and the numbers below the x-axis are the numbers of patients at risk. PSE = porto-
systemic encephalopathy. (a) Upper digestive bleeding. (b) Ascites. (c) Incidence of hepatocellular carcinoma. (d)
Survival after development of HCC in compensated and decompensated cirrhosis. (e) Portal systemic encephalopathy.
(f) Jaundice.
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same time. Overall, 206 patients (97%, Figure 3d) died
in this stage (29% after a new clinical event: bleeding
6%, ascites 3%, jaundice 7%, encephalopathy 19%).
Five-year transition towards a different prognostic
stage was respectively 34.5%, 42%, 65% and 78% in
stages 1–4 (P for trend <0.0001) and 5-year mortality in
stages 1–5 was respectively 1.5%, 10%, 20%, 30% and
88% (P for trend <0.0001) (Figure 4; Table 6).
Hepatocellular carcinoma occurred in stages 1–5 in
27, 28, 12, 30 and 29 patients respectively. All the
patients who developed HCC in stages 1 or 2 developed
one or more decompensating events before dying. The
median survival time for patients developing HCC in a
compensated stage was 15 months (range 2–96) and for
patients developing HCC in a decompensated stage it
was 3 months (range 1–35).
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Figure 3 | Competing risk analysis of 20-year major outcomes from each of ﬁve assessed prognostic stages of
cirrhosis. Each incidence curve represents the probability of each speciﬁc outcome summed to the outcome
probability represented in the next curve below. In the panels, the x-axis represents the observation time in months
and the numbers below the x-axis are the numbers of patients at risk. Boxes report 20-year occurrence rate of each
outcome. JauPse, Jaundice and/or encephalopathy; PSE, porto-systemic encephalopathy. (a) Stage 1; (b) Stage 2; (c)
stage 3; (d) stage 4; (e) stage 5.
Table 6 | Prognostic stages and outcome
Stage Deﬁnition
No. of
patients*
5-year transition
rate (%)
5-year mortality
rate (%)
1 Compensated cirrhosis without varices 202 34.5 1.5
2 Compensated cirrhosis with varices 216 42 10
3 Bleeding without other disease complications 75 65 20
4 First nonbleeding decompensating event 206 78 30
5 Any second decompensating event 213 – 88
* Total number of patients who entered in the stage during the study either at diagnosis or during follow-up.
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Exploratory prognostic analysis for mortality
Signiﬁcant death risk predictors are shown in Table 7.
As age was signiﬁcantly correlated with comorbidity
(mean  standard deviation 47  15 without and
53  11 with comorbidity; P < 0.00001), it was with-
drawn from the ﬁnal model to assess the prognostic role
of comorbidity. The variable stages showed an indepen-
dent prognostic value even when adjusted for other
important prognostic variables in cirrhosis including the
Child–Pugh score, the MELD and comorbidity. Besides
Child–Pugh score and the MELD, other signiﬁcant vari-
ables were albumin, bilirubin, log transformation of INR,
creatinine, hepatocellular carcinoma and comorbidity.
DISCUSSION
This study, based on a large cohort of cirrhotic patients
with complete follow-up, showed that a prognostic stag-
ing system based on major clinical manifestations of the
disease is suitable to classify patients according to signiﬁ-
cantly increasing risk of death, independently of Child–
Pugh or Meld score or comorbidity.
An important ﬁnding of the study is the very low
(14%) probability of death before decompensation for
compensated patients. This ﬁnding underlines the
appropriateness of considering the course of cirrhosis as
the progression across different prognostic stages.3 In
fact, the probability of dying while in a compensated
stage was markedly different from the probability
shown by the Kaplan–Meier method for patients with
compensated cirrhosis at diagnosis, without accounting
for transition in a decompensated stage (Figures 1a,b).
Importantly, while 10% of patients with compensated
cirrhosis died before decompensation of nonliver-related
causes, 4% died of their ﬁrst decompensating event,
suggesting that AoCLF30 may have a major role in
these critical events and potentially providing a measure
of the impact of AoCLF on the course of cirrhosis.
Unfortunately, complete data to characterise patients
according to the criteria for AoCLF were not available
in our database and therefore, we were not able to
properly assess the role of this event in mortality of
compensated patients.
By characterising patients according to the ﬁrst occur-
rence of the major clinical manifestations of the disease,
we assessed the disease progression from the time of
appearance of each speciﬁc manifestation, by a compet-
ing risks analysis. Following this approach, we conﬁrmed
that the proposed stages allowed to classify all the
patients with cirrhosis according to the major clinical
patterns of the disease, and are fairly characterised by a
steadily and signiﬁcant increase in mortality.
The competing risks analysis also showed that major
outcomes are appreciably different across stages. In fact,
varices and ascites are the major outcomes for patients
without varices at diagnosis, while bleeding and ascites
are the most important after the development of varices,
as rebleeding and ascites are for patients with a ﬁrst
bleeding without other complications. Ascites was by far
the most frequent decompensating event and any second
decompensating event was associated with mortality as
high as 88% in 5 years. Patients presenting with upper
digestive bleeding alone had a better survival than
patients presenting with any other decompensating
event; however, bleeding alone was observed in only
approximately half of the total of patients who bled (75/
158). In these patients, 5-year survival was 80% unless
they developed other complications (Figure 3c).
Hepatocellular carcinoma developed in 26% of patients
and survival after its occurrence was signiﬁcantly differ-
ent according to whether it developed in a compensated
or in a decompensated stage of cirrhosis (Figure 2d),
Stage 1
No varices
Stage 2
Varices
Stage 3
Stage 4
Stage 5:Second
Decompensating
event
Bleeding
First non bleeding
decompensation
88
48
30
20
10
1.5
21
20
45
4
1.51.59
8
DEATH
Figure 4 | Schematic representation of 5-year
transitioning rate across stages and to death for the
whole series of patients. Arrows represent transitions
and the numbers close to each arrow are the relevant
transition rates. A fairly steady increase in death rate
was found across stages.
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although it worsened prognosis either in compensated or
in decompensated disease. The poor outcome after devel-
opment of HCC may raise the question whether it
should be included in the criteria of decompensation,
although the increasing precocity of the diagnosis of
HCC in the compensated stages will tend to increase the
difference in survival of patients with HCC in compen-
sated compared to decompensated cirrhosis.
The staging system here proposed is easily applicable
in clinical practice and may have several favourable
implications: ﬁrst, it may allow to better deﬁne the dis-
ease outcomes so as to provide patients with more reli-
able information; second, it may allow to better classify
patients and to achieve more homogeneous data from
different centres or studies, particularly randomised clini-
cal trials; third, it may allow to identify more accurate
predictors of relevant outcomes, which in turn, may lead
to improved patient selection for speciﬁc therapies
including liver transplantation.
In an exploratory prognostic analysis, we sought to
assess whether the prognostic stages we have deﬁned
may retain any prognostic value when adjusted for sev-
eral important and widely used prognostic variables. The
analysis showed that the variable stages is an indepen-
dent and highly statistically signiﬁcant predictor of death
risk even when adjusted for comorbidity, Child–Pugh
score and MELD. This suggests that, if validated in fur-
ther studies, this prognostic staging system may provide
an important incremental value to the most widely used
prognostic scores. It is to note that, although comorbidi-
ty is usually not included in prognostic scores of cirrho-
sis, we included it in the analysis given its obvious
prognostic value conﬁrmed in a large population-based
cohort study.29 In fact, comorbidity was signiﬁcant in all
the three models we performed.
Besides the potential prognostic role of the staging
system here proposed, the marked differences in the
types and rates of outcomes observed across stages sug-
gest that prognostic indicators should be separately
assessed per each disease stage. It is in fact conceivable
that prognostic indicators may be different or may
have a different strength of association with the out-
come, across different stages. As an example, 1 mg
increase in serum bilirubin might have a different
prognostic value in compensated and decompensated
patients.
Table 7 | Exploratory prognostic analysis for death risk by the Cox model (494 patients)*
Variable†
Hazard
ratio
Standard
error
95% conﬁdence
interval P
Model 1
Albumin 0.97 0.009 0.96–0.99 0.005
Bilirubin 1.11 0.030 1.05–1.17 <0.0001
logINR 2.05 0.531 1.23–3.40 0.006
Creatinine 1.06 0.026 1.01–1.11 0.017
HCC 12.03 3.103 7.27–19.95 <0.0001
Comorbidity 1.44 0.157 1.16–1.79 0.001
Stage 1.44 0.082 1.23–1.61 <0.0001
Model 2
HCC 13.35 3.343 8.17–21.81 <0.0001
Comorbidity 1.46 0.157 1.19–1.81 <0.0001
Child–Pugh score 1.28 0.058 1.17–1.40 <0.0001
Stage 1.37 0.087 1.21–1.55 <0.0001
Model 3
Albumin 0.98 0.009 0.96–0.99 <0.0001
HCC 13.88 3.529 8.44–22.85 <0.0001
Comorbidity 1.49 0.161 1.20–1.84 <0.0001
MELD 1.09 0.017 1.06–1.12 <0.0001
Stage 1.41 0.079 1.27–1.58 <0.0001
HCC, hepatocellular carcinoma.
* Rating of variables included in the analyses was as follows: albumin, g/L (continuous values); bilirubin, mg/dL: ordinal values
with 1 mg/dL steps (0–1 = 1, etc.); INR = log(INR); creatinine, mg/dL: 0–1 = 1; 1.1–2 = 2; Hepatocellular carcinoma, no = 0;
yes = 1; comorbidity, no = 0, yes = 1; stage = 1–5 as reported in methods; Child–Pugh score = 5–15; MELD (model for end stage
liver disease) = continuous values.
† Age was withdrawn from the ﬁnal models because it was signiﬁcantly correlated with comorbidity.
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The observation that the type and rate of outcomes
are different according to different prognostic stages
has also been recently reported in a Danish cohort
study assessing the clinical course of alcoholic cirrho-
sis:7 although oesophageal varices were not considered
as a stratifying variable for compensated cirrhosis, tran-
sitioning across stages was roughly similar to what
observed in our study. In fact, the overall 5-year prob-
ability of developing a second decompensating event
after bleeding alone or ascites alone was respectively
54% and 42%,7 compared to 45% and 48% in our
study and 5-year mortality was respectively 18% and
25%,7 compared to 20% and 30% in our study. Simi-
larly, the signiﬁcantly higher decompensation rate of
patients with oesophago-gastric varices compared to
patients free of varices has also been previously
reported8, 9 and this observation is coherent with the
increased risk of decompensation with hepatic vein
pressure gradient >10 mmHg.32 Also the different out-
come of decompensated cirrhosis according to the
major clinical characteristics, and particularly the better
outcome of patients presenting with variceal bleeding
compared to patients presenting with ascites, was previ-
ously reported7 and recently conﬁrmed in a cohort
study of decompensated cirrhosis:33 these ﬁndings,
together with ours, support the appropriateness of con-
sidering bleeding alone as a separate prognostic stage
in decompensated cirrhosis.
However, although several studies6–12 have conﬁrmed
the rationale for a staging system in cirrhosis, a full inde-
pendent and prospective validation of the system here
proposed is needed before it may be applied in clinical
practice. It is of note, in this respect, that preliminary
results from a large multicentre study seem to validate
this staging system.34
One limitation of the present study is that only alco-
hol, virus related and cryptogenic cirrhosis has been
included and applicability of the proposed prognostic
stages to other aetiologies remains to be assessed. How-
ever, as the prognostic stages here proposed represent
major clinical manifestations of cirrhosis, it is conceiv-
able that this staging system may also apply to other
aetiologies. In fact, even if different outcome rates per
each stage may be predicted according to aetiology,
differences between stages may still be consistent across
different aetiologies. Of course, this hypothesis has to be
tested in further studies. It is of interest, in this respect,
that the Laennec’s histological stages of cirrhosis have
been recently reported to be signiﬁcantly related to
the clinical stages and to clinically signiﬁcant portal
hypertension;10–12 haemodynamic and biological correla-
tion with clinical stages has been advocated too.3
Another limitation of this study is that, no treatment
was given for HCV infection, for the reasons reported in
the method section. However, in this respect, it may be
worth to note that treatment with peginterferon-alpha
and ribavirin is expected to achieve a sustained viral
response (SVR) in approximately 22%35 of cirrhotic
patients; although the disease progression may be
delayed in these patients, it is conceivable that their out-
come will differ according to the development of major
clinical events. Therefore, the prognostic stages here pro-
posed, will be probably applicable even after anti-viral
treatment. Similarly, anti-viral treatment for HBV cirrho-
sis may halt the progression of the disease, although it
may be expected that even with anti-HBV treatment, the
outcome of patients who have developed clinical mani-
festations of the disease will be worse than that of
patients who have not. Yet, the role of ﬁbrosis regression
after sustained virological response either in HCV or in
HBV infection,36 in the clinical course of compensated
cirrhosis remains to be assessed, particularly after the
introduction of direct anti-viral agents for HCV,37 which
may signiﬁcantly increase SVR even in patients with cir-
rhosis. However, until more deﬁnitive information on
the long-term outcome of anti-viral treatments in cirrho-
sis either compensated or decompensated will be avail-
able, the prognostic staging system here proposed may
help to improve outcome prediction in clinical practice.
In conclusion, this large prospective inception cohort
study provides further insight in the clinical course of
cirrhosis, suggesting a new perspective which better
explains the different outcome of compensated and de-
compensated cirrhosis and shows that ﬁve prognostic
stages may contribute to improve the disease outcome
prediction, together with other important prognostic
indicators. The marked difference in outcome across
stages suggests that prognostic indicators should be
assessed separately per each disease stage.
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